# Gyre Therapeutics, Inc. (GYRE)

> Source: Nexqual · https://nexqual.com/GYRE · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Gyre Therapeutics, Inc. (GYRE), nexqual.com/GYRE" · informational, not investment advice.

**Price:** USD 6.4 (-1.08% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.47 · day 6.4–6.65 · 52w 5.44–9.42 · market cap $679M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 18.67 (range 18–20).
- Total return with dividends: 1Y -26.8% vs S&P 500 +18.1%; 5Y -34.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.12, revenue estimate $28.4M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 18.67 (low 18, high 20).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -26.8% | -34.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.9% | -8.1% |
| Volatility (annualized) | 55.1% | 103.0% |
| Max drawdown | -36.5% (Mar 2026→Jun 2026) | -91.0% (Oct 2021→May 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/GYRE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt